MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

By M. Bloomston, W. Frankel, F. Petrocca, Stefano Volinia, H. Alder, J. Hagan, Chang-Gong Liu, Darshna Bhatt, Cristian Taccioli, Carlo Maria Croce. Journal of the American Medical Association (JAMA), 2007

1,185 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/a1bfa0ae976b704af932371b415482e6c4282ee8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Surgery

Citations in the corpus

OncomiRs: the discovery and progress of microRNAs in cancers (2007, background): “High expression of miR-196a-2 was found to predict poor survival [52].”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “For example miR-21 expression has been reported at high levels in breast (Iorio et al, 2005), glioblastomas (Ciafre et al, 2005), pancreas (Bloomston et al, 2007) and colon cancer (Schetter et al, 2008) among others.”
miR-21: a small multi-faceted RNA (2008, background): “A group of pancreatic ductal adenocarcinoma patients with lower miR-21 expression demonstrated a 50% longer survival than the remainder of the patients tested, though it was not statistically significant due to the small number of tumours analysed [101].”
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells (2009, positive): “Interestingly, the Notch2 expression inhibition at the protein level by miR-34 was not accompanied by inhibition at the mRNA level, in agreement with previous reports that miRNA inhibits target gene expression post-transcriptionally, with or without mRNA degradation [11,20].”
MicroRNAs in development and disease. (2011, background): “Expression profiling of miRNAs in pancreatic cancer (PaCa) versus chronic pancreatitis identified upregulation of 15 and downregulation of 8 miRNAs that accurately classified 93% of the samples (47).”
MicroRNA signature predicts survival and relapse in lung cancer. (2008, background): “Several microRNAs were reported to be associated with the clinical outcome of chronic lymphocytic leukemia (Calin et al., 2005), lung adenocarcinoma (Takamizawa et al., 2004; Yanaihara et al., 2006), and breast (Iorio et al., 2005) and pancreas (Bloomston et al., 2007; Roldo et al., 2006) cancers.”
INCREASED HEPATIC SYNTHESIS AND DYSREGULATION OF CHOLESTEROL METABOLISM IS ASSOCIATED WITH THE SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE (2012, methodology): “RT-PCRwas performed in triplicates using an Applied Biosystems 7300 Sequence Detection system, as described by Bloomston (Bloomston et al., 2007).”
MicroRNA-125b is a novel negative regulator of p53. (2009, background): “…homolog of lin-4 essential for the temporal control of post-embryonic differentiation in Caenorhabditis elegans (Olsen and Ambros 1999), was also recently found to be elevated in several types of cancers (Nelson et al. 2006; Bloomston et al. 2007; Shi et al. 2007; Bousquet et al. 2008).”
MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, positive): “Furthermore, the global-expression pattern of miRNAs distinguished between long-term and short-term survivors of pancreatic cancer and also differentiated ductal adenocarcinomas of the pancreas from normal pancreas and chronic pancreatitis with 95% accuracy”
Genomic profiling of microRNA and mRNA reveals deregulated microRNA expression in prostate cancer (2008, background): “miR-196a was identified as a repressor of HOXB8 (37), and elevated expression of miR-196a predicts poor survival in pancreatic cancer (18).”
Reprogramming of miRNA networks in cancer and leukemia. (2010, neutral): “, E-TABM-664 (Bloomston et al. 2007), E-TABM-762 and E-TABM-763 (Visone et al. 2009), E-TABM-508 (Pichiorri et al. 2008) , E-TABM-429 (Garzon et al. 2008a), E-TABM-434 (Petrocca et al. 2008), E-TABM-405 (Garzon et al. 2008b), E-TABM-343 (Iorio et al. 2007), E-TABM-41 and E-TABM-42 (Calin et al. 2005”
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening (2009, methodology): “Furthermore, miRNA expression signatures have been used to predict prognosis.”